Skip to main content Help with accessibility Skip to main navigation

Upadacitinib

Indication

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)

NICE TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Red

Brand:

Nice TA:

768

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system Skin

Background

1.1 Upadacitinib, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 15 - Mar - 2022